- Home
- LNKB vs INBX Comparison
LNKB vs INBX Comparison
Compare LNKB & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | INBX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.2M | 999.7M |
| IPO Year | 2022 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LNKB | INBX |
|---|---|---|
| Price | $8.19 | $58.86 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.7K | ★ 143.2K |
| Earning Date | 04-27-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | ★ 26.76 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | $1,300,000.00 |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | N/A |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | 11.29 | ★ 550.00 |
| 52 Week Low | $6.09 | $10.81 |
| 52 Week High | $9.59 | $94.57 |
Technical Indicators
Market Signals| Indicator | LNKB | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 33.28 |
| Support Level | $8.07 | $28.54 |
| Resistance Level | $9.02 | $85.97 |
| Average True Range (ATR) | 0.21 | 4.27 |
| MACD | -0.01 | -0.55 |
| Stochastic Oscillator | 15.25 | 8.45 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.